[go: up one dir, main page]

HK1057489A1 - Medicament for treating chronic hepatitis b - Google Patents

Medicament for treating chronic hepatitis b

Info

Publication number
HK1057489A1
HK1057489A1 HK04100492A HK04100492A HK1057489A1 HK 1057489 A1 HK1057489 A1 HK 1057489A1 HK 04100492 A HK04100492 A HK 04100492A HK 04100492 A HK04100492 A HK 04100492A HK 1057489 A1 HK1057489 A1 HK 1057489A1
Authority
HK
Hong Kong
Prior art keywords
chronic hepatitis
lactoferrin
remedies
treating chronic
medicament
Prior art date
Application number
HK04100492A
Inventor
Akiharu Watanabe
Kiyohiro Higuchi
Hirotoshi Hayasawa
Susumu Teraguchi
Koji Yamauchi
Original Assignee
Morinaga Milk Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd filed Critical Morinaga Milk Industry Co Ltd
Publication of HK1057489A1 publication Critical patent/HK1057489A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Remedies for chronic hepatitis B which contain lactoferrin as the active ingredient; remedies for chronic hepatitis B which contain a mixture of lactoferrin, probiotics and prebiotics as the active ingredient; utilization of lactoferrin for producing remedies for chronic hepatitis B; utilization of a mixture of lactoferrin, probiotics and prebiotics for producing remedies for chronic hepatitis B; a method of treating chronic hepatitis B involving the administration of lactoferrin; and a method of treating chronic hepatitis B involving the administration of a mixture of lactoferrin, probiotics and prebiotics. Because of being less expensive and having no side effect, these remedies for chronic hepatitis B can be efficaciously used in the fields of drugs and food and drinks.
HK04100492A 2000-11-30 2004-01-21 Medicament for treating chronic hepatitis b HK1057489A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000365299 2000-11-30
PCT/JP2001/010490 WO2002043753A1 (en) 2000-11-30 2001-11-30 Remedies for chronic hepatitis b

Publications (1)

Publication Number Publication Date
HK1057489A1 true HK1057489A1 (en) 2004-04-08

Family

ID=18836097

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100492A HK1057489A1 (en) 2000-11-30 2004-01-21 Medicament for treating chronic hepatitis b

Country Status (5)

Country Link
JP (1) JP4087249B2 (en)
KR (1) KR20030045025A (en)
CN (1) CN1287855C (en)
HK (1) HK1057489A1 (en)
WO (1) WO2002043753A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100421656C (en) * 2002-11-07 2008-10-01 明尼苏达大学评议会 Use of ursodeoxycholic acid in the preparation of medicines for treating nervous system damage associated with hemorrhage
JP2005247780A (en) * 2004-03-05 2005-09-15 Masakazu Maruyama Viral hepatitis-treating agent
US20070224285A1 (en) * 2004-03-31 2007-09-27 Calpis Co., Ltd Agent for Preventing or Suppressing Hepatopathy and Functional Food for Preventing or Suppressing Hepatopathy
CA2609954A1 (en) 2005-06-29 2007-01-04 Nrl Pharma, Inc. Agent for ameliorating heavy metal-induced disorders, and medicinal composition, food and cosmetic containing the same
WO2008047391A1 (en) * 2006-10-17 2008-04-24 S.I.F.Fr.A. Farmaceutici Srl Nutriceutic composition comprising lactoferrin and proteasic probiotics
RU2560425C2 (en) * 2008-08-28 2015-08-20 Кр. Хансен А/С Stabiliser of colour in bacterial composition
CN107184613A (en) * 2017-05-23 2017-09-22 山东大学 A kind of probiotic composition for promoting hepatitis type B virus to remove and its application
CN119040216B (en) * 2024-10-25 2025-02-11 广东省科学院微生物研究所(广东省微生物分析检测中心) Bifidobacterium longum GY2 with anti-hepatitis B virus function and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2532911B2 (en) * 1988-03-01 1996-09-11 森永乳業株式会社 Composition for promoting intestinal colonization of useful bacteria
EP1116490A4 (en) * 1998-07-30 2004-08-04 Morinaga Milk Industry Co Ltd AGENTS IMPROVING HEPATIC FUNCTION
JP2000325046A (en) * 1999-05-19 2000-11-28 Meiji Milk Prod Co Ltd Foods or drugs that prevent and treat hepatitis

Also Published As

Publication number Publication date
CN1446099A (en) 2003-10-01
JP4087249B2 (en) 2008-05-21
KR20030045025A (en) 2003-06-09
WO2002043753A8 (en) 2003-03-06
JPWO2002043753A1 (en) 2004-04-02
CN1287855C (en) 2006-12-06
WO2002043753A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
CA2404387A1 (en) Theanine compositions for promoting sleep
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
TR200002299T2 (en) Epothilon compositions.
WO2001027109A3 (en) Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives
WO2006125819A3 (en) Oral microparticulate, anti-misuse drug formulation
HK1123213A1 (en) Reduction of dizziness, a side effect associated with pirfenidone therapy
SI1883387T1 (en) Container for liquid medicaments to be administered
WO2000053149A3 (en) Method and composition for administering a cyclooxygenase-2 inhibitor
HK1057489A1 (en) Medicament for treating chronic hepatitis b
WO2005081742A3 (en) Testosterone oral dosage formulations and associated methods
WO2001074365A3 (en) An efficacious dosage regimen of galantamine that reduces side effects
DE60222383D1 (en) MEDICAMENT FOR THE ADMINISTRATION OF AMIFOSTIN AND RELATED ACTIVE SUBSTANCES
MXPA04003851A (en) Antipruritics.
EP1197227A4 (en) Method of the administration of drugs having binding affinity with plasma protein and preparation to be used in the method
GB0018322D0 (en) Pharmaceutical compositions
EP1550443A4 (en) Composition against stress-related diseases
TW200509984A (en) Injectable dosage form of flupirtine
TW200514582A (en) Transdermal preparation and method for reducing side effect in pergolide therapy
NZ501987A (en) Single, high dosage intravenous administration of estramustine phosphate
EP1219297A4 (en) Antiobestic agents
MXPA03002114A (en) Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals.
IL164921A0 (en) Synergistic interaction of abacavir and alovudine
MY136408A (en) Active substance combinations and therapies for treating abuse of alcohol
WO2002028380A3 (en) Oral dosage forms for administration of the combination of tegafur, uracil, folinic acid, and irinotecan and method of using the same
EP1311286A4 (en) Treatment of hepatitis c with thymosin and pegylated interferon

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE CHINESE NAME OF INVENTOR

Effective date: 20040811

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181130